Table 1.
Patient demographic and clinical characteristics (n = 46).
Fig 1.
Systolic PAP as a function of cumulative t-PA dose for each patient (light lines).
Mixed-effects regression model (dense line) revealed a significant linear decrease in systolic PAP (β = -0.37 (SE = 0.05), p < 0.001).
Table 2.
Mean systolic pulmonary artery pressure and cumulative t-PA dose at follow-up intervals.
Fig 2.
(A) Changes in severity of right heart strain on echocardiography from baseline to follow-up (p<0.001). (B) Changes in right heart strain on echocardiography stratified by total t-PA dose. (C) Decrease in RV/LV diameter ratio on CT from baseline to follow-up (p<0.001).
Table 3.
Safety outcomes (n = 46).
Fig 3.
Comparison of t-PA dose effect on systolic pulmonary artery pressure in prior CDT studies for submassive pulmonary embolism.
* 28 mg t-PA or 2,67,101 International units of urokinase.
Table 4.
Comparison of bleeding complications to prior studies.